WO2024005756 - ORAL DOSAGE FORMULATIONS COMPRISING EMPAGLIFLOZIN
National phase entry is expected:
Publication Number
WO/2024/005756
Publication Date
04.01.2024
International Application No.
PCT/TR2023/050592
International Filing Date
20.06.2023
Title **
[English]
ORAL DOSAGE FORMULATIONS COMPRISING EMPAGLIFLOZIN
[French]
FORMULATIONS POSOLOGIQUES ORALES COMPRENANT DE L'EMPAGLIFLOZINE
Applicants **
SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI
Istınye Mahallesı Balabandere Caddesı No:14
34460 Sarıyer/Istanbul, TR
Inventors
GULER, Tolga
Istınye Mahallesı Balabandere Caddesı No:14
34460 Sarıyer/Istanbul, TR
ARMUT, Merve
Istınye Mahallesı Balabandere Caddesı No:14
34460 Sarıyer/Istanbul, TR
PEHLIVAN AKALIN, Nur
Istınye Mahallesı Balabandere Caddesı No:14
34460 Sarıyer/Istanbul, TR
SUNEL, Fatih
Istınye Mahallesı Balabandere Caddesı No:14
34460 Sarıyer/Istanbul, TR
Priority Data
2022/010736
29.06.2022
TR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
Turkpatent
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 993 | |
| EPO | Filing, Examination | 4810 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 2710 |
Total: 9674 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to oral dosage formulations comprising Empagliflozin or a pharmaceutically acceptable salt thereof and at least one filler wherein Empagliflozin or pharmaceutically acceptable salt has a d (0.9) particle size higher than 150 µm.[French]
La présente invention concerne des formulations posologiques orales comprenant de l'empagliflozine ou un sel pharmaceutiquement acceptable de celle-ci et au moins une charge ; l'empagliflozine ou le sel pharmaceutiquement acceptable ayant une taille de particule d (0,9) supérieure à 150 µm.